The largest of these studies (n=82) was a pooled analysis of two similarly designed Phase II, randomized, double-blind, placebo-controlled, multicenter trials of treatment with anamorelin, a ghrelin-receptor agonist, for cancer cachexia in patients with various advanced, incurable cancers (breast, colon, lung, genitourinary and others; Eastern Cooperative Oncology Group Score of ≤2) and cachexia defined as a weight loss of ≥5 within the previous 6months (Garcia et al. 2015). The gene discussed is GHSR; the disease is Cachexia.